Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical has announced the proposed spin-off listing of its subsidiary, Fosun Adgenvax, on the Hong Kong Stock Exchange. Fosun Adgenvax specializes in vaccines and has several products approved for marketing in mainland China, with others in various stages of clinical trials. This strategic move aims to enhance Fosun Adgenvax’s market presence and operational focus, though the listing is still in the preliminary planning stage.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a Chinese joint stock company primarily engaged in the pharmaceutical industry. The company focuses on the research, development, production, and sales of vaccines for human use, with a strong emphasis on both bacterial and viral vaccines.
Average Trading Volume: 10,511,559
Technical Sentiment Signal: Buy
Current Market Cap: HK$80.2B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.